Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
38265
CAS Number:
242478-38-2
Succinate de solifénacine
Purity:
≥ 98 % (HPLC)
Synonym(s):
(1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl3,4dihydro-1-phényl-2(1 H )-iso-quinoléinecarboxylatesuccinate
Documents
$97.25 /25 mg
Taille
Request Bulk Quote
Informations sur le produit

Solifenacin succinate is a potent antimuscarinic agent primarily utilized in the management of overactive bladder conditions. This compound works by selectively inhibiting muscarinic receptors, thereby reducing involuntary bladder contractions and improving urinary control. Its unique structure allows for a favorable pharmacokinetic profile, making it an effective choice for patients seeking relief from symptoms such as urgency, frequency, and incontinence.

In clinical settings, Solifenacin succinate has demonstrated significant efficacy in enhancing the quality of life for individuals suffering from urinary disorders. Its application extends beyond urology, as ongoing research explores its potential benefits in other therapeutic areas, including gastrointestinal and neurological disorders. With a well-established safety profile and a convenient dosing regimen, Solifenacin succinate stands out as a reliable option for healthcare professionals aiming to provide effective symptom management for their patients.

Numéro CAS 
242478-38-2
Formule moléculaire
C23H26N2O2 · C4H6O4
Poids moléculaire 
480.56
Point de fusion 
145 - 149 °C
Rotation optique 
[a] 20 D = 35 - 45 ° (C = 1 dans H2O)
Informations générales
Numéro CAS 
242478-38-2
Formule moléculaire
C23H26N2O2 · C4H6O4
Poids moléculaire 
480.56
Point de fusion 
145 - 149 °C
Rotation optique 
[a] 20 D = 35 - 45 ° (C = 1 dans H2O)
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Solifenacin succinate is widely utilized in research focused on:

  • Overactive Bladder Treatment: This compound is primarily used in the pharmaceutical industry to manage symptoms of overactive bladder, providing relief from frequent urination and urgency.
  • Pharmacological Studies: Researchers study its efficacy and safety profile, helping to develop better therapeutic strategies and improve patient outcomes.
  • Combination Therapies: Solifenacin succinate is often explored in combination with other medications to enhance treatment effectiveness for urinary disorders.
  • Patient Compliance Research: Its once-daily dosing schedule makes it a focus in studies aimed at improving adherence to treatment regimens among patients.
  • Drug Development: The compound serves as a model in drug formulation research, allowing scientists to investigate new delivery methods and formulations for improved bioavailability.

Citations